Mice with a CML-like disease relapse with ALL under STI571 treatment

被引：0
|
作者：
Miething, C [1 ]
Grundler, R [1 ]
Hoepfl, J [1 ]
Mugler, C [1 ]
Gschaidmeier, H [1 ]
Peschel, C [1 ]
Duyster, J [1 ]
机构：
[1] Tech Univ Munich, D-8000 Munich, Germany
来源：
EXPERIMENTAL HEMATOLOGY | 2002年 / 30卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
240
引用
收藏
页码：96 / 96
页数：1
相关论文
共 50 条
  • [1] Mice with a CML-like disease relapse with an acute lymphocytic leukemia after treatment with STI571.
    Miething, C
    Grundler, R
    Hoepfl, J
    Mugler, C
    Peschel, C
    Duyster, J
    [J]. BLOOD, 2001, 98 (11) : 714A - 715A
  • [2] STI571 as a targeted therapy for CML
    O'Dwyer, ME
    Mauro, MJ
    Druker, BJ
    [J]. CANCER INVESTIGATION, 2003, 21 (03) : 429 - 438
  • [3] STI571, a molecularly targeted treatment modality for CML.
    Buchdunger, E
    Peng, B
    Ford, J
    Capdeville, R
    Resta, D
    Druker, B
    Sawyers, C
    Talpaz, M
    [J]. CLINICAL CANCER RESEARCH, 2000, 6 : 4482S - 4482S
  • [4] Histologic and cytogenetic relapse and progression in CML patients treated with STI571 (GLEEVEC)
    Hasserjian, RP
    Chase, A
    Dhar, S
    Olavarria, E
    Lampert, I
    Henry, K
    Apperley, JF
    Goldman, JM
    [J]. LABORATORY INVESTIGATION, 2002, 82 (01) : 244A - 244A
  • [5] Histologic and cytogenetic relapse and progression in CML patients treated with STI571 (GLEEVEC)
    Hasserjian, RP
    Chase, A
    Dhar, S
    Olavarria, E
    Lampert, I
    Henry, K
    Apperley, JF
    Goldman, JM
    [J]. MODERN PATHOLOGY, 2002, 15 (01) : 244A - 244A
  • [6] Successful allogeneic transplantation after treatment of blast crisis CML with STI571
    Deininger, MWN
    Schäfer, K
    Sayer, H
    Russel, N
    Peschel, C
    Gratwohl, A
    Goldman, J
    Hochhaus, A
    Guilhot, F
    Gambacorti-Passerini, C
    O'Brian, S
    Arcese, W
    Kolb, H
    AlAli, H
    Hegenbart, U
    Lange, T
    Capdeville, R
    Niederwieser, D
    [J]. BONE MARROW TRANSPLANTATION, 2001, 27 : S37 - S38
  • [7] Trial of IFN or STI571 before proceeding to allografting for CML?
    R Hehlmann
    [J]. Leukemia, 2000, 14 : 1560 - 1562
  • [8] STI571: Targeting BCR-ABL as therapy for CML
    Mauro, MJ
    Druker, BJ
    [J]. ONCOLOGIST, 2001, 6 (03): : 233 - 238
  • [9] Imatinib mesylate (STI571) for myeloid malignancies other than CML
    Krystal, GW
    [J]. LEUKEMIA RESEARCH, 2004, 28 : S53 - S59
  • [10] STI571: A tyrosine kinase inhibitor for the treatment of CML - Validating the promise of molecularly targeted therapy
    Druker, BJ
    [J]. FASEB JOURNAL, 2002, 16 (04): : A134 - A134
12345